Back to discover
Drug

Ketamine

In clinical development
Actively researchedLate-stage developmentRising momentum
Also known as 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone, 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone, DL-ketamine+9 more

2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone, 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone, DL-ketamine, Ketalar, Ketaset, Zetamine, (+-)-Ketamine, (±)-ketamine, Ketamina, Kétamine, Ketamine Hydrochloride, Ketaminum.

45
Research papers
36
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Neurobiology of Suicide

Clinical trial2026-07-16Results expected Q3 2030 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ketamine
Aliases & brands
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone2-(methylamino)-2-(2-chlorophenyl)cyclohexanone2-(o-chlorophenyl)-2-(methylamino)-cyclohexanoneDL-ketamineKetalarKetasetZetamine(+-)-Ketamine(±)-ketamineKetaminaKétamineKetamine HydrochlorideKetaminum
RxNorm CUI
6130
ChEMBL ID
CHEMBL742
ATC codes
N01AX03
UNII
690G0D6V8H

Clinical trials

195 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
195
registered trials across all phases
LATEST COMPLETION 2026
36
Active studies
30
Recruiting
123
Late-stage (III+)
87
Completed
72
Discontinued
PHASE DISTRIBUTIONn = 195
Early Phase 110Phase 117Phase 1 / 29Phase 236Phase 2 / 39Phase 324Phase 454Phase N / A36

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

45 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19952025
Most influential
Recent papers
Major research themes8
Ketamine16Antidepressive Agents4Depression3Hallucinogens3Brain2Depressive Disorder, Treatment-Resistant2Neuronal Plasticity2Receptors, N-Methyl-D-Aspartate2
Journals, researchers & institutions
Top journals
  • Biological psychiatry4
  • Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology4
  • Anesthesiology3
  • Molecular psychiatry3
  • Anesthesia and analgesia2
  • CNS neuroscience & therapeutics2
Leading researchers
  • Zarate CA Jr5
  • Nugent AC4
  • Ballard ED3
  • Charney DS3
  • Park LT3
  • Akeju O2
  • Brown EN2
  • Brutsche NE2
Leading institutions
free-text, unnormalised
  • National Institute of Mental Health7
  • Yale School of Medicine3
  • Division of Clinical Neuroscience2
  • Harvard Medical School2
  • Laboratory of Neurotherapeutics2
  • Massachusetts General Hospital2

Related diseases

4 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 4 of the same disease areas as Ketamine in the shared literature.

4 shared diseases4 shared papers

Studied across 7 of the same disease areas as Ketamine in the shared literature.

7 shared diseases1 shared paper

Studied across 3 of the same disease areas as Ketamine in the shared literature.

3 shared diseases2 shared papers

Studied across 3 of the same disease areas as Ketamine in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Ketamine in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Ketamine in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Ketamine in the shared literature.

3 shared diseases1 shared paper

Studied across 2 of the same disease areas as Ketamine in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials